From: Selective activation of TCR-γδ+ cells in endemic Burkitt's lymphoma
Subset | Healthy controls | eBL patients | Difference | P(T)* | |
---|---|---|---|---|---|
CD3+** | - | 81.7 [76.4 to 86.4] | 66.5 [47.6 to 72.1] | -15.4 [-34.1 to -7.5] | <0.001 |
CD19+** | - | 0.4 [0.2 to 1.0] | 5.8 [4.8 to 8.8] | 5.4 [4.2 to 8.4] | <0.001 |
CD3+ | CD4+ | 63.5 [53.6 to 65.7] | 68.0 [57.8 to 75.0] | 5.0 [-1.9 to 13.1] | 0.11 |
CD3+ | CD8+ | 27.8 [26.6 to 31.7] | 20.9 [16.6 to 29.7] | -6.0 [-11. 5 to 1.8] | 0.08 |
CD3+ | TCR-γδ+ | 7.5 [4.9 to 15.5] | 3.3 [2.6 to 5.4] | -3.6 [-7.9 to -1.2] | 0.006 |
TCR-γδ+ | Vγ 9+ | 45.2 [34.8 to 59.8] | 18.8 [14.2 to 29.8] | -25.2 [-35.4 to -15.1] | <0.001 |
TCR-γδ+ | V δ 2+ | 32.3 [12.3 to 45.1] | 9.2 [6.9 to 13.9] | -2 1.2 [-3 1.2 to -4.8] | 0.007 |
TCR-γδ+ | V δ 3+ | 7.7 [5.0 to 11. 7] | 9.8 [5.4 to 14.3] | 2.2 [-1.9 to 6.6] | 0.25 |
TCR-γδ+ | CD4+ | 4.8 [3.7 to 9.6] | 7.5 [4.9 to 34.8] | 2.9 [0.1 to 24.2] | 0.04 |
TCR-γδ+ | CD8+ | 31.2 [26.4 to 48.3] | 36.6 [26.0 to 45.9] | 0.0 [-8.0 to 11.0] | 0.98 |